Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer - AstraZe

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer.
The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of adjuvant chemotherapy.
Related: AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting.
This is the third BTD for Enhertu in breast cancer. Enhertu previously received BTDs to treat second-line HER2 positive metastatic breast cancer in 2021 and later-line HER2 positive metastatic breast cancer in 2017.
Two additional BTDs for ENHERTU were also granted in 2020 for HER2 mutant non-small cell lung cancer and HER2 positive metastatic gastric cancer.
Price Action: AZN shares are up 2% at $66.36 during the premarket session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.